China SXT Pharmaceuticals, Inc. (SXTC) Operating margin 2017–2026
China SXT Pharmaceuticals, Inc. (SXTC) operating margin by fiscal year — reported operating income divided by reported revenue.
-625.9%FY2026 · since FY2017: 32.8% → -625.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -625.9% | -471.9 pp |
| FY2025 | -154.0% | -23.5 pp |
| FY2024 | -130.4% | +154.0 pp |
| FY2023 | -284.4% | -85.0 pp |
| FY2022 | -199.4% | -153.4 pp |
| FY2021 | -46.0% | -20.0 pp |
| FY2020 | -26.0% | -51.2 pp |
| FY2019 | 25.2% | +2.0 pp |
| FY2018 | 23.3% | -9.6 pp |
| FY2017 | 32.8% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice